I patienternes egne rapporteringer vha. en ublindet vurdering på en symptomskala i begge forsøg, var oral og iv topotecan forbundet med samme symptomlindring hos patienter med recidiverende, sensitiv SCLC.
Oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive SCLC in patient self- reports on an unblinded symptom scale assessment in each of these two studies.